In a report released on August 11, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with a price target of $44.00. The company’s shares closed last Friday at $27.06.
According to TipRanks, Canino is an analyst with an average return of -28.4% and a 26.25% success rate. Canino covers the Healthcare sector, focusing on stocks such as Kura Oncology, Zentalis Pharmaceuticals, and Arvinas Holding Company.
Zentalis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $49.88, which is an 84.33% upside from current levels. In a report released on August 10, Wells Fargo also maintained a Buy rating on the stock with a $50.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $31.49 and a one-year low of $15.55. Currently, Zentalis Pharmaceuticals has an average volume of 860.7K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZNTL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company’s product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
Read More on ZNTL:
- Zentalis expects cash to fund operations into 2026
- Zentalis reports Q2 EPS ($1.85), consensus ($1.04)
- Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Zentalis appoints Freeman as Chief Strategy Officer
